Eloxx Pharmaceuticals logo

Eloxx PharmaceuticalsNASDAQ: ELOX

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

26 April 1999

Next earnings report:

25 November 2024

Last dividends:

N/A

Next dividends:

N/A
$314.34
-100%vs. 3y high
1%vs. sector
-vs. 3y high
-vs. sector
-100%vs. 3y high
17%vs. sector
-vs. 3y high
-vs. sector

Price

regular market | Wed, 20 Nov 2024 14:30:00 GMT
$0.00$0.00(0.00%)

Dividend

No data over the past 3 years
No data over the past 3 years

Analysts recommendations

Institutional Ownership

ELOX Latest News

Eloxx Pharmaceuticals Provides Pipeline and Financing Updates
globenewswire.com11 July 2024 Sentiment: POSITIVE

First two subjects dosed in Phase 1 clinical trial of ZKN-013; ZKN-013 is being developed for the potential treatment of rare dermatological and other diseases associated with nonsense mutations

Off the Beaten Path: 3 Delisted Stocks for The Speculative Investor
InvestorPlace05 December 2023 Sentiment: POSITIVE

While getting kicked off an exchange typically signals about the biggest warning sign you can possibly receive, a (somewhat) rational argument exists for delisted stocks to buy. Psychologically, companies go through much anxiety doing whatever they can to stay listed in a major exchange.

This Small Cap Stock Surged Over 100%
MarketBeat12 July 2023 Sentiment: POSITIVE

Arguably the most impressive mover yesterday was a stock you have probably never heard of. Shares of Eloxx Pharmaceuticals NASDAQ: ELOX rocketed almost 100% yesterday after receiving an increased price target from Oppenheimer.

Why Is Eloxx Pharmaceuticals (ELOX) Stock Down 27% Today?
InvestorPlace16 May 2023 Sentiment: NEGATIVE

Eloxx Pharmaceuticals (NASDAQ: ELOX ) stock is falling hard on Tuesday after the company provided a weak earnings report for Q1 2023. The bad news for ELOX stock starts with its losses per share of $2.88 cents.

Senesco Technologies Inc. (ELOX) Reports Q1 Loss, Lags Revenue Estimates
Zacks Investment Research15 May 2023 Sentiment: NEGATIVE

Senesco Technologies Inc. (ELOX) came out with a quarterly loss of $2.88 per share versus the Zacks Consensus Estimate of a loss of $2.55. This compares to loss of $5.20 per share a year ago.

What type of business is Eloxx Pharmaceuticals?

Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribosome modulation for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial for the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The company also develops various preclinical programs for the treatment of alport syndrome, recessive dystrophic epidermolysis bullosa, junctional epidermolysis bullosa, and familial adenomatous polyposis, as well as various earlier discovery stage programs in oncology. Eloxx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Watertown, Massachusetts.

What sector is Eloxx Pharmaceuticals in?

Eloxx Pharmaceuticals is in the Healthcare sector

What industry is Eloxx Pharmaceuticals in?

Eloxx Pharmaceuticals is in the Biotechnology industry

What country is Eloxx Pharmaceuticals from?

Eloxx Pharmaceuticals is headquartered in United States

When did Eloxx Pharmaceuticals go public?

Eloxx Pharmaceuticals initial public offering (IPO) was on 26 April 1999

What is Eloxx Pharmaceuticals website?

https://www.eloxxpharma.com

Is Eloxx Pharmaceuticals in the S&P 500?

No, Eloxx Pharmaceuticals is not included in the S&P 500 index

Is Eloxx Pharmaceuticals in the NASDAQ 100?

No, Eloxx Pharmaceuticals is not included in the NASDAQ 100 index

Is Eloxx Pharmaceuticals in the Dow Jones?

No, Eloxx Pharmaceuticals is not included in the Dow Jones index

When was Eloxx Pharmaceuticals the previous earnings report?

No data

When does Eloxx Pharmaceuticals earnings report?

The next expected earnings date for Eloxx Pharmaceuticals is 25 November 2024